Innate Pharma S.A. (OTCMKTS:IPHYF) Short Interest Down 8.8% in August

Innate Pharma S.A. (OTCMKTS:IPHYF) was the recipient of a significant decrease in short interest during the month of August. As of August 15th, there was short interest totalling 6,200 shares, a decrease of 8.8% from the July 31st total of 6,800 shares. Based on an average daily volume of 500 shares, the short-interest ratio is currently 12.4 days.

Innate Pharma Stock Up 9.5 %

IPHYF stock opened at $2.30 on Monday. Innate Pharma has a 12 month low of $1.93 and a 12 month high of $3.00. The firm’s 50-day moving average is $2.12 and its 200 day moving average is $2.38.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.